,00,-08-05

PTO/SB/21 (09-04)
DIOG. OMB 0651-0031
ENT OF COMMERCE
OMB control number.

· · · · · · · · · · · · · · · · · · ·	and Deduction Act of 4001	U.	PTO/SB/21 (09 Approved for use through 07/31/2006. OMB 0651-0 S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMER
Under the Paperwork Reduction Act of 1995. no persons TRANSMITTAL		Application Number	a collection of information unless it displays a valid OMB control num 09/807,647
		Filing Date	April 16, 2001
, cer	ADEMIN'S FORM		S. Oi
ADEM			1624
		Examiner Name	B. Kifle
	all correspondence after initial	Attorney Docket Number	
Total Number of	Pages in This Submission		all that apply)
Amendme Af Af Af Extension Express A Information Certified C Documen Reply to M Incomplet	fter Final ffidavits/declaration(s) n of Time Request Abandonment Request on Disclosure Statement Copy of Priority	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revoca Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Remarks	After Allowance Communication to Tomporation of Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Return Postcard Appendix A (copy of previously submitted Information Disclosure Statement and cop of related transmittal papers)
Firm Name	SIGNA	TURE OF APPLICANT, ATT	TORNEY, OR AGENT
Signature	5,	M Ramed	
Printed name Elaine M. Ramesh			
Date	, ,	05	Reg. No. 43,032
		ERTIFICATE OF TRANSMIS	SSION/MAILING
I hereby certify the sufficient postage the date shown be	at this correspondence is to as first class mail in an en	peing facsimile transmitted to the US velope addressed to: Commissioner	PTO or deposited with the United States Postal Service with r for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 or
sufficient postage	at this correspondence is to as first class mail in an en	peing facsimile transmitted to the US Ivelope addressed to: Commissioner	SPTO or deposited with the United States Postal Service with r for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 or

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/17 (10-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Juction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FÉË TRAN		Complete if Known		
FEE IRAN	SWITTAL	Application Number	09/807,647	
for FY	2005	Filing Date	April 16, 2001	
Effective 10/01/2004. Patent fees are		First Named Inventor	S. Oi	
		Examiner Name	B. Kifle	
Applicant claims small entity status. See 37 CFR 1.27		Art Unit	1624	
TOTAL AMOUNT OF PAYMENT	(\$) 120.00	Attorney Docket No.	2560 US0P	

Check Credit card Money Order None Deposit Account: Deposit Account Number Deposit Account Name Takeda Chemical Ind. Ltd. Name The Director Is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments Charge any additional fee(s) or any underpayment of fee(s) Charge fee(s) indicated below, except for the filling fee to the above-identified deposit account. TEE CALCULATION ACCOUNT None Samall Entity Small Entity Surcharge - late filing fee or oath Indicated filing fee or oath Indicated filing fee or cover sheet Indicated filing fee or oath Indicated filing fee or	
Deposit Account Deposit Account Account Number Deposit Account Name Takeda Chemical Ind. Ltd. Name The Director Is authorized to: (check all that apply) Charge fee(s) indicated below Charge any additional fee(s) or any underpayment of fee(s) Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account. FEE CALCULATION Large Entity Small Entity Fee Fee Code (\$) Code (
Deposit Account Number Deposit Account Number Deposit Account Name Takeda Chemical Ind. Ltd. Name The Director Is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account. FEE CALCULATION Fee Fee Code (\$) Fee Fee Code (\$) Fee Per	
Account Number Deposit Account Name Takeda Chemical Ind. Ltd. Name The Director is authorized to: (check all that apply) Charge fee(s) indicated below Charge any additional fee(s) or any underpayment of fee(s) Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account. Takeda Chemical Ind. Ltd. 1051 130 1052 50 1053 130 1053 130 1053 130 1053 130 1053 130 1053 130 1053 130 1054 Pequesting publication of SIR prior to Examiner action 1804 920* Requesting publication of SIR after Examiner action 1805 1,840* 1805 1,840* 1805 1,840* 1805 1,840* 1805 1,840* 1806 1,840* 1807 Requesting publication of SIR after Examiner action 1806 1,840* 1807 Requesting publication of SIR after Examiner action 1808 1,840* 1809 1,840* 1	
Deposit Account Name The Director Is authorized to: (check all that apply) Charge fee(s) indicated below Charge any additional fee(s) or any underpayment of fee(s) Charge fee(s) indicated below, except for the filling fee to the above-identified deposit account. The Director Is authorized to: (check all that apply) Credit any overpayments 1052 50 1053 130 1053 130 Non-English specification 1812 2,520 1804 920* Requesting publication of SIR prior to Examiner action 1805 1,840* Requesting publication of SIR after Examiner action 1251 110 1251 110 1252 150 1253 130 Non-English specification 1804 920* Requesting publication of SIR prior to Examiner action 1804 920* Requesting publication of SIR after Examiner action 1805 1,840* Requesting publication of SIR after Examiner action 1251 110 1251 110 1251 110 1251 110 1252 130 1805 1,840* Requesting publication of SIR after Examiner action 1251 110 1251 110 1251 110 1251 110 1251 110 1251 110 1252 130 1804 920* Requesting publication of SIR after Examiner action 1251 110 12	
Name The Director Is authorized to: (check all that apply) Charge fee(s) indicated below Charge any additional fee(s) or any underpayment of fee(s) Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account. FEE CALCULATION 1053 130 Non-English specification 1812 2,520 For filing a request for ex parte reexamination 1814 920* Requesting publication of SIR prior to Examiner action 1815 1,840* Requesting publication of SIR after Examiner action 1816 1,840* Requesting publication of SIR after Examiner action 1817 1,840* Requesting publication of SIR after Examiner action 1818 2,520 For filing a request for ex parte reexamination 1819 2,520 For filing a request for ex parte reexamination 1810 1,840* Requesting publication of SIR after Examiner action 1818 2,520 For filing a request for ex parte reexamination 1819 2,520 For filing a request for ex parte reexamination 1819 2,520 For filing a request for ex parte reexamination 1810 1,840* Requesting publication of SIR after 1810 1,840* Re	
Charge fee(s) indicated below Credit any overpayments Charge fee(s) indicated below Credit any overpayment of fee(s) Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account. 1812 2,520 1812 2,520 1812 2,520 1812 2,520 1812 2,520 1814 920* Requesting publication of SIR prior to Examiner action 1805 1,840* Requesting publication of SIR after Examiner action 1805 1,840* Requesting publication of SIR after Examiner action 1805 1,840* Requesting publication of SIR after Examiner action 1805 1,840* Requesting publication of SIR after Examiner action 1806 1,840* Requesting publication of SIR after Examiner action 1807 1,840* Requesting publication of SIR after Examiner action 1808 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action 1809 1,840* Requesting publication of SIR after Examiner action	
Charge fee(s) indicated below Credit any overpayments Charge any additional fee(s) or any underpayment of fee(s) Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the above-identified deposit account. The control of the filing fee to the filing fee to the above-identified deposit account. The control of the filing fee to the filing fee to the above-identified deposit account. The control of the filing fee to the filing fee to the above-identified deposit account. The control of the filing fee to the filing fee to the above-identified deposit account.	
Charge any additional ree(s) or any underpayment of ree(s) Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account. Second Fee (s) indicated below, except for the filing fee to the above-identified deposit account. 1805 1,840* 1805 1,840* Requesting publication of SIR after Examiner action	7
to the above-identified deposit account. FEE CALCULATION 1251 -110 2251 55 Extension for reply within first month 1252 430 2252 215 Extension for reply within second month	\dashv
FEE CALCULATION 1251 110 2251 55 Extension for reply within first month 1252 430 2252 215 Extension for reply within second month	
TEE CALCULATION 1252 430 2252 215 Extension for reply within second month	
1. BASIC FILING FEE Large Entity Small Entity 1253 980 2253 490 Extension for reply within third month	
Fee Fee Fee Fee Description Fee Paid 1254 1.530 2254 765 Extension for reply within fourth month	
Code (\$)	
1001 790 2001 399 Unity ming ree	
1002 350 2002 175 Design filing fee 1401 340 2401 170 Notice of Appeal 1402 340 2402 170 Filing a brief in support of an appeal 1402 340 2402 170 Filing a brief in support of an appeal	7
1004 790 2004 395 Reissue filing fee 1403 300 2403 150 Request for oral hearing	
1005 160 2005 80 Provisional filing fee 1451 1,510 Petition to institute a public use proceeding	\neg
Aug aug of Palific to action and additional and action action and action action and action action and action acti	
SUBTOTAL (1) (\$) 1452 110 2452 55 Petition to revive - unavoidable 1453 1,330 2453 665 Petition to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1501 1,370 2501 685 Utility issue fee (or reissue)	\Box
Extra Claims below Fee Paid 1502 490 2502 245 Design issue fee	
Total Claims20** = X	
Claims 1460 130 Petitions to the Commissioner	
Multiple Dependent 300 = 1807 50 Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity Fee Fee Fee Fee Description 1806 180 Submission of Information Disclosure Stmt	_
Fee Fee Fee Fee Fee Fee Fee Bescription Code (\$) Code (\$) Code (\$) Code (\$) Code (\$) Code (\$) Recording each patent assignment per property (times number of properties)	
1202 18 2202 9 Claims in excess of 20 1809 790 2809 395 Filing a submission after final rejection	\dashv
1201 88 2201 44 Independent claims in excess of 3 (37 ČFR 1.129(a))	\dashv
1203 300 2203 150 Multiple dependent claim, if not paid 1810 790 2810 395 For each additional invention to be examined (37 CFR 1.129(b))	\Box
1204 88 2204 44 ** Reissue independent claims over original patent 1801 790 2801 395 Request for Continued Examination (RCE)	[
1205 18 2205 9 ** Reissue claims in excess of 20 1802 900 Request for expedited examination of a design application	
Other fee (specify)	コ
*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 120.00	可

SUBMITTED BY				(Complete (if applicable))
Name (Print/Type)	Elaine M. Ramesh, Ph.D., JD	Registration No. (Attorney/Agent)	43,032	Telephone	847-383-3391
Signature	Elsene M	Lunesh		Date	6/7/05

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, usprio to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.





United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. DOX 1450 Alexandria, Vinginis 22313-1450

		www.mshm@n4	
U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATT	Y. DOCKET NO:
09/807,647	Satoru Oi	2560USOP	
		INTERNATIONAL AP	PLICATION NO.
23115		PCT/JP99/	05754
TAKEDA PHARMACEUTICALS NORTH	I AMERICA, INC	LA. FILING DATE	PRIORITY DATE
INTELLECTUAL PROPERTY DEPARTM 475 HALF DAY ROAD SUITE 500	ENG E I V E	10/19/1999	10/20/1998
LINCOLNSHIRE, IL 60069	MAY 1 4 2004	CONFIRM 371 ACCEPTANCE	

Date Mailed: 05/10/2004

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495

I.P. DEPT.

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

04/16/2001

DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS

<u>06/29/2001</u>

DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. THE DATE APPEARING ON THE FILING RECEIPT AS THE "FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE. The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Copy of the International Application filed on 04/16/2001
- Copy of the International Search Report filed on 04/16/2001
- Copy of IPE Report filed on 04/16/2001
- Biochemical Sequence Diskette filed on 04/21/2004
- Oath or Declaration filed on 04/16/2001
- Biochemical Sequence Listing filed on 04/21/2004
- Copy of references cited in ISR filed on 04/16/2001
- U.S. Basic National Fees filed on 04/16/2001
- Priority Documents filed on 04/21/2004

U.S. Patent Application Serios NO. 09/807, 1047

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

KAYA L LEWIS BALTIMORE Telephone: (703) 305-3695

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/903 (371 Acceptance Notice)



₩ext

Int'l Alpha Country Code

Acceptance Clerk Initials

x600678

847

POST OFFICE ADDDECCE





) ZIP Code

IS OMER USE ONLY

press Mail Corporate Acct.

FROM: (PLEASE PRINT)

ite In

POST OFFICE TO ADDRESSEE

Flat Rate Envelope

Return Receipt Fee

Total Postage &

nsurance Fe

TO: (PLEASE PRINT)

BOX PCT

COD Fee

Postage

\$



SEE REVERSE SIDE FOR

SERVICE GUARANTEE AND LIMITS ON INSURANCE COVERAGE

WAIVER OF SIGNATURE (Domestic Only): Additional merchandise insurance is void if walver of algnature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize

COMMISSIONER DE PATENTS AND TRADEMARKS WASHINGTON DC 20231-0001

ature constitutes valid proof of delivery.

Customer Copy Label 11-F August 2000

Customer Copy Label 11-F August 2000

F02

F02 T12

401

401

MARK CHAD:
TAKEDA PHARMACEUTICALS
AMERICA INC
475 HALF DAY RD STE 50
LINCOLNSHIRE 500 IL 60069-2935

FOR PICKUP OR TRACKING CALL 1-800-222-1811

383-3372

Docket #2560 USOP

POSTAL SERVICE

***** WELCOME TO ***** LINCOLNSHIRE PO LINCOLNSHIRE, IL 60069-9998 04/16/01 04:41PM

Store USPS Trans Wkstn sys5002 Cashier's Name Stock Unit Id Cashier KK14SH Greg GREGSSA PO Phone Number 847-634-3260

1. Exp. Mail PO-ADD Destination: 0.00 20231 51b 4.30oz Weight: Postage Type: Total Cost: Base Rate: None 27.30 27.30 EL784119258US Label#: Corporate Acct.: 600672 27.30 Amount Charged:

Subtotal Total

0.00

Number of Items Sold: 1

Thank You Please come again!

ro-13		ENT OF COMMERC	E PATENT AND TRADEMARK OFFICE	ATTO PS DOCKET NUMBER			
,2-29-99 T'D	ANSMITTAL LETTER	TO THE I	INITED OTATED	2560US0P			
110							
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371							
	DITTO VALUE OF THE CONTROL OF THE CO						
	P99/05754	October 19,		PRIORITY DATE CLAIMED October 20, 1998			
TITLE C	OF INVENTION 45 D			I			
4 P.P. 10 4	1,5-Benzodiazepine Compounds, Their Production and Use						
APPLICA	NT(S) FOR DO/EO/US Satoru O	l et al.					
	herewith submits to the United States	s Designated/Ele	ected Office (DO/EO/US) the follo	owing items and other information:			
1. 🔀							
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3	This express request to begin nations examination until the expiration of the	al examination p	procedures (35 U.S.C. 371(f)) at an	ny time rather than delay			
4. X	A proper Demand for International P	reliminary Exam	nination was made by the 19th mo	onth from the earliest claimed priority date.			
5. X	A copy of the International Appl	ication as filed	(35 U.S.C. 371(c)(2))				
			if not transmitted by the Intern	national Bureau).			
	b. X has been transmitted by						
6. X	c. \square is not required, as the ap A translation of the International		filed in the United States Rece				
7.	Amendments to the claims of the						
			if not transmitted by the Inter				
	b. have been transmitted b						
	[]		e limit for making such amend	ments has NOT expired.			
	d. have not been made and	will not be m	ade.				
8.	A translation of the amendments	to the claims	under PCT Article 19 (35 U.S.	C. 371(c)(3)).			
9. X	An oath or declaration of the inv	entor(s) (35 U	S.C. 371(c)(4)).				
10.	10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
Items 1	l 1. to 16. below concern documen	ıt(s) or inform	nation included:	•			
11. X	An Information Disclosure States	ment under 37	CFR 1.97 and 1.98.				
12. X	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13.	A FIRST preliminary amendment.						
	A SECOND or SUBSEQUENT preliminary amendment.						
14.	A substitute specification.						
15.	A change of power of attorney and/or address letter.						
16. X	Other items or information:						
	1) Sequence Listing (Paper & Co	mputer-readal	ole copies)	•			
	2) Sequence Listing Statement						
-							
			* This includes specification	n 221 total pages, including			
			Claims 1-18 (9 pgs), Abstralisting (4 pgs).	act (1 pg), and Sequence			
			noding (+ pgs) .	·			

U.S. Patent Application School No. 09/807, 647

Express Mail Label #: EL 784119258US Date: 4/16/01 Docket # : 2560US0P Applicants: Satoru OI et al.

Title: "1,5-Benzodiazepine Compounds, Their Production and Use"

Kindly acknowledge receipt of the accompanying:

1) This PTO Return Receipt Postcard

2) Transmittal letter (2 pgs X 2)

3) A Translation of the International Application into English [This includes Specification 221 total pages, including Claims 1-18 (9 pgs.), Abstract (1 pg.), and Sequence Listing (4 pgs.)] 4) Executed Declaration

- 5) Information Disclosure Statement with PTO form 1449, and IDS citations (6), and the International Search Report
- 6) Executed Assignment and assignment cover sheet (and one copy of the 7) Sequence Listing Statement

8) Sequence Listing (Paper & Computer-readable copies)

09/807647

Docket #: 2560US0P Express Mail Label #: EL 784119258US Date: 4/16/01

Applicants: Satoru OI et al.

Title: "1,5-Benzodiazepine Compounds, Their Production and Use"

Kindly acknowledge receipt of the accompanying:

- 1) This PTO Return Receipt Postcard JC07 Rec'd PCT/PTO T 6 APR 2001
- 3) A Translation of the International Application into English [This includes Specification 221 total pages, including Claims 1-18 (9 pgs.), Abstract (1 pg.), and Sequence Listing (4 pgs.)]

4) Executed Declaration

- 5) Information Disclosure Statement with PTO form 1449, and copies of IDS citations (6), and the International Search Report
- 6) Executed Assignment and assignment cover sheet (and one copy of the cover sheet)

7) Sequence Listing Statement

8) Sequence Listing (Paper & Computer-readable copies)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

tba

Art Unit:

tba

Filed:

tba

Examiner:

1st Inventor:

Satoru OI

llowed:

For:

1.5-Benzodiazepine Compounds, Their Production and Use

Batch:

Atty. Dkt. No.

2560 US0P

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EL 784119258 US

DATE IN: April 16, 2001

Itemized Papers/Items:

- 1. This certificate and a Return Receipt Postcard (2 pgs.)
- 2. Transmittal Letter for Filing under 35 USC 371 (2 pgs. X 2)
- 3. English Translation of the International Application as filed in Japanese [This includes Specification 221 total pages, including Claims 1-18 (9 pgs.), Abstract (1 pg.) and Sequence Listing (4 pgs.)]
- 4. Executed Declaration/Power of Attorney (4 pgs.)
- 5. Information Disclosure Statement (2 pgs.) with PTO form 1449 (1 pg.), and copies of IDS citations (6), and the International Search Report (2 pgs.)
- 6. Executed Assignment (2 pgs.) and assignment cover sheet (1 pg. X 2)
- 7. Sequence Listing Statement (1 pg.)
- 8. Sequence Listing (Paper & Computer-readable copies) (2 pgs.)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

BOX PCT

Commissioner for Patents Washington, D.C. 20231.

on this date, 4/16/01.

Gail L. Winokur

Dated:

EL784119258US